Please wait





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person:  (1) The number represents shares of common stock, $0.001 par value (the "Common Stock") of Regulus Therapeutics Inc. (the "Issuer") held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. (2) Based on 69,234,089 shares of Common Stock outstanding as of May 2, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on May 8, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person:  (1) The number represents shares of Common Stock of the Issuer held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. (2) Based on 69,234,089 shares of Common Stock outstanding as of May 2, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q, filed with the SEC on May 8, 2025.


SCHEDULE 13G



 
Vivo Opportunity Fund Holdings, L.P.
 
Signature:/s/ Kevin Dai
Name/Title:Kevin Dai/Managing Member
Date:05/14/2025
 
Vivo Opportunity, LLC
 
Signature:/s/ Kevin Dai
Name/Title:Kevin Dai/Managing Member
Date:05/14/2025